ABBOTT LABORATORIES AND NAPRO BIOTHERAPEUTICS FILE PACLITAXEL ANDA

07-Mar-2001

Abbott Laboratories (NYSE: ABT) and NaPro BioTherapeutics, Inc. (Nasdaq: NPRO) announced today that they have filed an Abbreviated New Drug Application (ANDA) with the U.S. food and Drug Administration (FDA) for paclitaxel, the most widely used anticancer compound in the United States.

"Abbott is building a superior portfolio of oncology products," said Christopher B. Begley, senior vice president, hospital products, Abbott Laboratories. "Submitting the paclitaxel ANDA is a major milestone in Abbott's plan to expand our presence in the oncology market."

"We are very hopeful that soon oncologists and cancer patients in the United States will have another high quality paclitaxel option," commented Leonard P. Shaykin, chairman and chief executive officer, NaPro BioTherapeutics.

Other news from the department research and development

Most read news

More news from our other portals

Discover the latest developments in battery technology!